## Indeterminate Leprosy: Drug of Choice **Key Point:** Indeterminate leprosy is the earliest, smear-negative form of leprosy. According to WHO MDT guidelines and Park's Textbook of Preventive and Social Medicine (26th ed.), indeterminate leprosy is treated with **Dapsone monotherapy (100 mg daily for 6 months)** — not Rifampicin monotherapy. ### Classification Context Indeterminate leprosy precedes the tuberculoid–lepromatous spectrum. It presents with: - Single (or very few) hypopigmented macule(s) - Impaired sensation - Negative slit-skin smear (Bacteriological Index = 0) - No definitive histological features of tuberculoid or lepromatous type ### WHO / NLEP Regimen for Indeterminate Leprosy | Parameter | Detail | |---|---| | Drug | **Dapsone 100 mg daily** (self-administered) | | Duration | **6 months** | | Rationale | Bacterial load is negligible; monotherapy with a bacteriostatic agent is sufficient | > Park's Textbook of Preventive and Social Medicine (26th ed., Ch. 8 — Leprosy): *"Indeterminate leprosy is treated with Dapsone 100 mg daily for 6 months."* ### Why Not the Other Options? - **A — Rifampicin + Dapsone + Clofazimine (MB-MDT):** Reserved for multibacillary leprosy (BI ≥ 1 or ≥ 6 lesions). Overkill for indeterminate leprosy with negligible bacterial load. - **C — Rifampicin monotherapy:** Not the standard regimen for indeterminate leprosy in WHO/NLEP/Park guidelines. Rifampicin is used as the supervised monthly dose in PB-MDT (combined with Dapsone), not as a standalone agent for indeterminate disease. - **D — Ofloxacin monotherapy:** Not a standard first-line regimen for any leprosy type; used as an alternative in single-dose ROM (Rifampicin + Ofloxacin + Minocycline) for single-lesion PB leprosy. ### Comparison with Other Leprosy Types | Leprosy Type | Smear | Regimen | Duration | |---|---|---|---| | **Indeterminate** | Negative | **Dapsone monotherapy** | **6 months** | | Tuberculoid / PB (1–5 lesions) | Negative | Rifampicin 600 mg/month + Dapsone 100 mg/day | 6 months | | Multibacillary (≥6 lesions) | Positive | Rifampicin + Dapsone + Clofazimine | 12 months | | Single-lesion PB | Negative | ROM (single dose) | Single dose | **Clinical Pearl:** If the patient develops additional lesions or nerve involvement during follow-up, reclassify to PB leprosy and upgrade to PB-MDT (Rifampicin + Dapsone for 6 months). [cite: Park's Textbook of Preventive and Social Medicine, 26th ed., Ch. 8; NLEP Guidelines]
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.